Author

Ailsa L Hart

JAK to the future: a patient-centric choice in UC (Galapagos)
JAK to the future: a patient-centric choice in UC (Galapagos)

Ailsa L Hart  et al.

Mistakes in pouchitis and how to avoid them
Mistakes in pouchitis and how to avoid them

Ailsa L Hart  et al.

Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)
Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)

Ailsa L Hart  et al.

Targeting IL-12/23 in ulcerative colitis: from evidence to bedside (Janssen)
Targeting IL-12/23 in ulcerative colitis: from evidence to bedside (Janssen)

Ailsa L Hart  et al.

Fire in the hole: What to do with anal strictures, fissures, refractory fistula and painful tags in CD?
Fire in the hole: What to do with anal strictures, fissures, refractory fistula and painful tags in CD?

Ailsa L Hart

Mistakes in pouchitis
Mistakes in pouchitis

Ailsa L Hart

JAK inhibition and individualised care: comprehensive management in UC (Galapagos) (Complete Session)
JAK inhibition and individualised care: comprehensive management in UC (Galapagos) (Complete Session)

Ailsa L Hart  et al.

Exhausted perianal disease
Exhausted perianal disease

Ailsa L Hart  et al.

EFFECTS OF EARLY MUCOSAL HEALING AT WEEK 10 USING STRINGENT CRITERIA IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH OZANIMOD ON CLINICAL OUTCOMES AT WEEK 52
EFFECTS OF EARLY MUCOSAL HEALING AT WEEK 10 USING STRINGENT CRITERIA IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH OZANIMOD ON CLINICAL OUTCOMES AT WEEK 52

Ailsa L Hart  et al.

It takes two to tango in UC: let’s get in sync with our patients (Pfizer Inc.) (Complete Session)
It takes two to tango in UC: let’s get in sync with our patients (Pfizer Inc.) (Complete Session)

Ailsa L Hart  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

Ailsa L Hart  et al.

HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Ailsa L Hart  et al.

FACTORS ASSOCIATED WITH CHRONIC ABDOMINAL PAIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PILOT CROSS-SECTIONAL STUDY
FACTORS ASSOCIATED WITH CHRONIC ABDOMINAL PAIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PILOT CROSS-SECTIONAL STUDY

Ailsa L Hart  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Ailsa L Hart  et al.

European consensus conference on faecal microbiota transplantation in clinical practice
European consensus conference on faecal microbiota transplantation in clinical practice

Ailsa L Hart  et al.

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Ailsa L Hart  et al.

QUANTIFICATION OF STEM CELL DYNAMICS AND CRYPT FISSION RATES IN INFLAMMATORY BOWEL DISEASE
QUANTIFICATION OF STEM CELL DYNAMICS AND CRYPT FISSION RATES IN INFLAMMATORY BOWEL DISEASE

Ailsa L Hart  et al.

DEVELOPMENT AND INTERNAL-EXTERNAL VALIDATION OF A DYNAMIC MULTIVARIABLE PREDICTION MODEL FOR ADVANCED COLORECTAL NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
DEVELOPMENT AND INTERNAL-EXTERNAL VALIDATION OF A DYNAMIC MULTIVARIABLE PREDICTION MODEL FOR ADVANCED COLORECTAL NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Ailsa L Hart  et al.

DETAILED MAPPING OF COPY NUMBER ALTERATIONS IN THE INFLAMMATORY BOWEL DISEASE COLON REVEALS LARGE CLONAL EXPANSIONS AND PATTERNS OF CONVERGENT EVOLUTION
DETAILED MAPPING OF COPY NUMBER ALTERATIONS IN THE INFLAMMATORY BOWEL DISEASE COLON REVEALS LARGE CLONAL EXPANSIONS AND PATTERNS OF CONVERGENT EVOLUTION

Ailsa L Hart  et al.

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Ailsa L Hart  et al.

Item 1 - 20 / 22
1
2